Bradley beefs up reps for launch

Share this article:
Bradley Pharmaceuticals is hiring about 60 reps as it gears up to launch Elestrin, a low-dose estrogen gel for treating the symptoms of menopause.

The reps will pitch Elestrin to OB/GYNs as part of Bradley's Kenwood Therapeutics division, which received FDA approval for the product last December.

The company estimates the size of the US estrogen therapy market, which consists of oral and topical products, at $1.3 billion. The topical market is only worth about $300 million. Bradley in-licensed Elestrin from BioSante Pharmaceuticals late last year and has the exclusive US marketing rights.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...